DEPO Depomed, Inc. (delisted)

Depomed, Inc. (NASDAQ:DEPO) today announced that members of senior management will participate at the 2018 UBS Global Healthcare Conference in a session scheduled for 1:30 pm ET on Tuesday, May 22, 2018 in New York, NY.

This presentation will be webcast and can be accessed via the Investor Relations page of the Depomed website at www.depomed.com.  A recording of the webcasts will be archived for 30 days.

About DepomedDepomed is a leading specialty pharmaceutical company committed to putting the patient first in everything it does. Depomed is focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain businesses and its emerging Orphan Specialty Business is focused on orphan drug indications and areas of unmet medical need. To learn more about Depomed, visit www.depomed.com.

INVESTOR AND MEDIA CONTACTS:

John B. Thomas SVP, Investor Relations and Corporate Communications jthomas@depomed.com